Prismic has the worldwide rights (except for Italy and Spain) for micro-PEA (palmitoylethanolamide). PEA is a naturally occurring anti-inflammatory that is produced within human cells in response to inflammation. Micronization allows PEA to be orally bio-available. The micronization technique was invented by Epitech and is protected by patents until 2030.
As a potent analgesic and anti-inflammatory agent, micro-PEA is expected to be effective in many inflammatory diseases such as chronic pain, arthritis, endometriosis, and various auto-immune disorders. In addition, there is some published data to suggest that micro-PEA may also have the potential to be an opioid-sparing agent.